Haleos Labs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Track the latest Haleos Labs Ltd. share price on Univest. Haleos Labs, formerly known as SMS Lifesciences India Ltd, is heading into Haleos Labs Q2 results after a Q1 FY27 that showed a clear recovery from a weak March 2026 quarter. Investors following Haleos Labs Q2 results will want to see whether that recovery in margins and profit continues into the September 2026 quarter.

Q1 FY27 revenue Rs 72.94 crore, OPM 12.5%, net profit Rs 1.84 crore. CMP Rs 1,493, PE 28.59, ROE 8.44%, market cap Rs 451 crore.

Haleos Labs Q2 results will be the first quarterly print since the company's rebranding to fully reflect the new corporate identity in reported financials, even though the underlying business and its historical numbers remain those of the same listed entity. This preview sticks strictly to reported, historical figures and does not estimate any number for the unreported September 2026 quarter.

Open a free demat account with Univest and track Haleos Labs ahead of results

When Will Haleos Labs Announce Q2 FY27 Results

No board meeting date has been announced yet for the September 2026 quarter, so a confirmed date for Haleos Labs Q2 results is not available at this stage. Based on the historical pattern for companies of similar size on the NSE, September-quarter results are typically filed between the last week of October and mid-November, and the actual date for Haleos Labs Q2 results will be known only once the exchange filing is made.

What to Expect from Haleos Labs Q2 Results

Also read – Jagran Prakashan Q2 Results FY27 Preview

No specific number is projected for Haleos Labs Q2 results here, since the September 2026 quarter has not been reported. Qualitatively, the key theme heading into Haleos Labs Q2 results is margin stability, given that operating margin dropped sharply to 5.54% in Mar26 before recovering to 12.5% in Jun26. Whether Haleos Labs can sustain double-digit operating margin, closer to the 14-17% band seen in Jun25, Sep25 and Dec25, is the qualitative question that will define how Haleos Labs Q2 results is received.

Q1 FY27 (June 2026 Quarter) Performance: The Base Going Into Q2

In the June 2026 quarter, right before Haleos Labs Q2 results, Haleos Labs reported revenue of Rs 72.94 crore, an operating profit of Rs 9.12 crore, an operating margin of 12.5%, and a net profit of Rs 1.84 crore. This was a meaningful improvement over the preceding Mar26 quarter, when net profit had fallen to just Rs 0.35 crore on an operating margin of only 5.54%, so Jun26 represents a partial recovery quarter ahead of Haleos Labs Q2 results.

Q2 FY26 (September 2025 Quarter): The Base Quarter for Comparison

The year-ago quarter that Haleos Labs Q2 results will be compared against is Sep25, which was actually the strongest of the five quarters reviewed here. Haleos Labs reported revenue of Rs 81.37 crore, an operating profit of Rs 13.58 crore, an operating margin of 16.69%, and a net profit of Rs 6.42 crore in that quarter. Because Sep25 was a high base on both margin and profit, Haleos Labs Q2 results faces a relatively demanding year-ago comparison.

Start investing with Univest and follow Haleos Labs' quarterly numbers live

Recent Trend Across the Last Five Quarters

Revenue across the five quarters moved from Rs 82.5 crore in Jun25 to Rs 81.37 crore in Sep25, up to Rs 94.78 crore in Dec25, then down to Rs 75.14 crore in Mar26 and Rs 72.94 crore in Jun26. Operating margin has been the more volatile line, moving from 14.19% to 16.69%, then 14.82%, a sharp fall to 5.54%, and a partial recovery to 12.5%. Net profit mirrored this pattern, falling from a peak of Rs 6.65 crore in Dec25 to just Rs 0.35 crore in Mar26 before recovering to Rs 1.84 crore in Jun26. This dip-and-recovery pattern is the most important trend to carry into any reading of Haleos Labs Q2 results.

Key Factors to Watch Ahead of Haleos Labs Q2 Results

Also read – Jagsonpal Pharmaceuticals Q2 Results FY27 Preview

The most important factor ahead of Haleos Labs Q2 results is whether operating margin can move back toward the mid-teens seen in the Jun25 to Dec25 quarters, rather than staying near the lower levels seen in Mar26. Second, given the company's recent rebranding from SMS Lifesciences India Ltd, any commentary on new product lines, capacity or client relationships under the new identity will be relevant context for Haleos Labs Q2 results. Third, revenue has been gradually declining over the last three quarters, from Rs 94.78 crore to Rs 72.94 crore, so a stabilisation in the topline would be a meaningful positive signal ahead of Haleos Labs Q2 results.

Valuation Snapshot Ahead of Q2 Results

At a current market price of Rs 1,493, Haleos Labs trades at a trailing PE of 28.59 and a price-to-book ratio of 2.11 on a book value of Rs 706 per share. Return on equity is 8.44%, the debt-to-equity ratio is 0.44, and the dividend yield is 0.1%. The 52-week range is Rs 1,091.1 to Rs 1,774, with the stock trading just below its 50-day moving average of Rs 1,507.06 and above its 200-day moving average of Rs 1,396.04, while the RSI of 48.04 points to a neutral setup heading into Haleos Labs Q2 results. Market capitalisation stands at around Rs 451 crore.

What to Watch When Haleos Labs Q2 Results Are Announced

When Haleos Labs Q2 results is announced, the key checkpoints are whether operating margin holds above the 12% level seen in Jun26 or slips back toward the Mar26 low, and whether net profit shows sequential improvement from the Rs 1.84 crore reported in Jun26. Commentary on the business under the new Haleos Labs identity, including any change in product mix, will also be worth reading alongside Haleos Labs Q2 results.

Conclusion

Haleos Labs enters the September 2026 quarter on the back of a partial margin recovery in Jun26, following a weak Mar26 quarter, and against a strong Sep25 year-ago base. Haleos Labs Q2 results will be an important data point in confirming whether the margin recovery seen in the June quarter is durable. No specific number is forecast for Haleos Labs Q2 results in this preview; only the officially reported figures should be relied upon once they are filed.

Explore Haleos Labs and other pharma-linked stocks on the Univest app

Disclaimer: Univest Securities Private Limited is a SEBI-registered Research Analyst (Registration No. INH000013776). This article is for educational and informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Figures cited are historical, publicly disclosed quarterly financials and current market data; no specific Q2 FY27 results, estimates, or forecasts are implied. Please consult a SEBI-registered investment adviser and verify data independently before making any investment decision.

FAQs

When will Haleos Labs announce its Q2 FY27 results?

Ans. No official date has been announced yet. Based on the historical pattern for Haleos Labs Q2 results, September-quarter results are usually filed between late October and mid-November, subject to the board meeting intimation.

What was Haleos Labs' net profit in Q1 FY27?

Ans. In the June 2026 quarter, the quarter before Haleos Labs Q2 results, Haleos Labs reported a net profit of Rs 1.84 crore on revenue of Rs 72.94 crore, with an operating margin of 12.5%.

Why did Haleos Labs' margin fall sharply in the March 2026 quarter?

Ans. In Mar26, operating margin fell to 5.54% from 14.82% in the previous quarter and net profit dropped to just Rs 0.35 crore, the weakest quarter in the five-quarter history relevant to Haleos Labs Q2 results, before a partial recovery in Jun26.

What is Haleos Labs' current valuation ahead of Q2 results?

Ans. As of the latest data, Haleos Labs trades at a PE of 28.59 and a PB of 2.11, with an ROE of 8.44% and a market capitalisation of about Rs 451 crore, at a current market price of Rs 1,493.